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Synthesis of [(1,2,3-Triazol-1-yl)methyl]boronic Acids Through Click1
Chemistry: Easy Access to a Potential Scaffold for Protease Inhibitors
Chiara Romagnoli,[a] Emilia Caselli,[a] and Fabio Prati*[a]
Keywords: Synthetic methods / Boron / Cycloaddition / Click chemistry / Bioisosters / Medicinal chemistry / Enzyme
inhibitors
Stereoselective synthesis of previously unreported [(1,2,3-6
triazol-1-yl)methyl]boronic acids has been achieved from azi-
domethylboronates by copper-catalyzed azide–alkyne cyclo-
addition reaction. The proximity of the cycloaddition reaction
center to the boronic group is not detrimental to the stability
Introduction
α-Amidomethylboronic acid is a recurring core-structure16
in biologically active and important boron-containing com-
pounds.[1] After the approval of Velcade® (Figure 1) and
clarification on the safety issues relating to boron-contain-
ing compounds, the use of this element in pharmaceutical
research has become an attractive “hot” topic. As a result,21
several boron derivatives are currently in preclinical and
clinical stage development.[2] Among other compounds, bo-
ronic acids exhibit excellent properties as competitive and
reversible protease inhibitors. Owing to their unique struc-
tural features, they act as transition state analogs: boron,26
with its open shell, interacts with nucleophilic active resi-
dues and in doing so converts from a neutral trigonal struc-
ture into an anionic tetrahedral adduct, which mimics the
high-energy intermediate in the amide hydrolysis process.
The boron moiety acts as the “warhead” blocking the cata-31
lytic site, whereas the α-amido group enhances molecular
recognition by mimicking natural substrates.[3]
The α-amidomethylboronate unit is the basic structure
of peptidoboronic acids, a class of peptidomimetics largely
explored to target different clinically relevant proteases. For36
example, anticancer compound Velcade® (A) is a dipeptid-
ylboronic acid (Phe-boroLeu) that acts as a proteasome in-
hibitor, whereas derivatives of the type Val-boroPro or Pro-
boroAla have been investigated as dipeptidyl peptidase-4 in-
hibitors for the treatment of diabetes.[4] The same skeleton41
is also part of simpler acylamidomethylboronic acids, which
have been reported to be subtilisin and α-chymotripsin in-
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of the sp3 C–B bond or to the stereoisomeric composition, 11
which further expands the field of application of click chem-
istry to new boronate substrates and offers a new potential
scaffold for protease inhibitors.
Figure 1. a. Examples of α-amidomethylboronic acids found in bio-
logically active compounds. b. Bioisosteric amide replacement with
1,4-disubstituted 1,2,3-triazoles.
hibitors and used as fluorescent carbohydrate sensors.[5] In
accordance with these developments, we investigated acyl-
amidomethylboronic acids B and C (Figure 1, a) as potent 46
and selective β-lactamase inhibitors.[6]
During our investigation, we were intrigued by the effect
of α-amido group replacement with 1,4-disubstituted 1,2,3-
triazole, which is a known non-classical amide bioisoster
(Figure 1, b). These two groups share several chemical 51
properties such as planarity, size, dipole moment and
hydrogen bond forming capabilities. However, they also
have important differences: triazole hopping can restrict
conformational flexibility and improve hydrolysis and oxid-
ation stability.[7] Furthermore, 1,4-disubstituted 1,2,3-tri- 56
azoles are easily accessible through copper-catalyzed azide–
alkyne cycloaddition (CuAAC) reaction, which is a pre-
ferred protocol because it proceeds under mild conditions
with inexpensive reagents, and with high versatility, high
efficiency, and straightforward product isolation.[8] For 61
these reasons, click chemistry is increasing in popularity in
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drug discovery and the use of triazole units as amide surro-
gates is becoming routine in structure activity relationship
studies.[9]
Surprisingly, this strategy has never been applied to α-66
amidomethylboronic acids, and [(1,2,3-triazol-1-yl)methyl]-
boronic acids are an unexplored scaffold. Investigation in
this field has probably been discouraged by the known abil-
ity of copper to insert into the C–B bond. Actually, this
activation is exploited in several useful cross-coupling reac-71
tions, such as in a copper-variant of the Suzuki–Miyaura
reaction and in the Chan–Lam C–N and C–O coupling re-
action with boronates.[10] However, these methods can lead
to degradation-promoting protodeboronation. To date,
some efforts on click reactions applied to boron derivatives76
have been done, but these have been restricted to arylboron-
ates, probably owing to their greater availability and sta-
bility. Moreover, in these cases the alkyne and azide in-
volved in the CuAAC reaction are remote with respect to
the boronic moiety and the few examples reported in the81
literature proceed with some difficulties  ((=Author:
do you agree with the change?))  . Some unique ap-
proaches have been tried, such as fluoride addition to stabi-
lize the C–B bond or inversion of the step sequence to insert
the boron atom after the CuAAC reaction.[11] The literature86
reports a single case in which the boronic group was directly
linked to the alkyne and produced a 1,2,3-triazole-4-
boronate.[12]
The first milestone of our project was to assess the feasi-
bility of synthesis of [(1,2,3-triazol-1-yl)methyl]boronic91
acids.
Results and Discussion
Initial experiments focused on the synthesis of the sim-
plest boronic ester, which corresponding to triazolyl ana-
logs of acyl-boroGly (Scheme 1).96
By starting from pinanediyl (chloromethyl)boronate
(1),[13] substitution with sodium azide was catalyzed by
tetrabutylammonium iodide, as a phase transfer agent, to
yield the (azidomethyl)boronate 2 (97%).[14] The use of (+)-
pinanediol to esterify the boronic acid group is justified by101
its strong stability to hydrolysis, which allows the use of
TLC as a reaction monitoring method. An investigation of
CuAAC reaction feasibility on azido intermediate 2 was
performed with ethyl propiolate as the acetylene counter-
part, which was chosen because of the general observation106
that α-carbonyl groups are more reactive than alkyl- or
Scheme 1. Synthesis of triazolyl analog of acyl-boroGly 3a. Tested conditions for the CuAAC reaction: a) CuI, DIPEA, THF; b) CuI,
lutidine, CHCl3; c) CuSO4, sodium ascorbate, tBuOH, H2O; TMSCl = trimethylsilyl chloride.
www.eurjoc.org © 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 0000, 0–02
aryl-alkynes.[15] From the wide variety of conditions de-
scribed in the literature for CuAAC reactions, we selected
three. In two cases the copper(I) catalyst was added directly
in the presence of a ligand [CuI, N,N-diisopropylethylamine 111
(DIPEA), tetrahydrofuran (THF), or CuI, lutidine,
CHCl3].[16] In the third case, the catalytically active metal
was generated in situ by reduction of copper sulfate
(CuSO4, sodium ascorbate, tert-butanol, H2O).[8] Each ex-
periment was performed at room temperature for 6 h with 116
a molar ratio of 2/ethyl propiolate/catalyst 1:1.5:0.1. The
crude product was analyzed by 1H NMR spectroscopy and
LC–MS, and formation of expected and previously unre-
ported product 3a in almost complete conversion was ob-
served in all of the three experiments, which confirms the 121
robustness of the CuAAC reaction. Nevertheless, when the
CuI catalyst was adopted, the NMR spectra revealed the
presence of proto-deboronation by-products (5–20%), and
these were more pronounced when more basic DIPEA
rather than lutidine was used as ligand. However DIPEA 126
could be easily removed from the crude mixture under re-
duced pressure, whereas lutidine could not. Superior per-
formance in terms of purity of the recovered material and
absence of deboronation by-products was observed under
aqueous conditions. Consequently there conditions were 131
therefore applied to the cycloaddition reactions of 2 with
several other alkynes. Among the many compounds com-
mercially available, carbonyl, aromatic, and aliphatic alk-
ynes were chosen. In the optimized procedure, azide 2 and
an excess of alkyne (1.5 equiv.) were dissolved in a 1:1 mix- 136
ture of tert-butanol and water, together with copper sulfate
(0.05 equiv.), which was reduced in situ by sodium ascorb-
ate (0.2 equiv.). The cyclization reactions were carried out
at room temperature and monitored by TLC until no azido-
methylboronate 2 remained. Complete conversion was 141
reached in two hours with propiolic acid and ethyl pro-
piolate (Table 1, Entries 1–2), whereas longer reaction times
(up to 16 h) were required for alky- and aryl-alkynes
(Table 1, Entries 3–5). The expected 1,4-disubstituted tri-
azoles were easily isolated by extraction, and any residual 146
alkyne was removed under reduced pressure, to afford 3a–
3e in good to excellent yields (85–99%) with high purity.
The cyclic product was confirmed by the presence of a sing-
let signal downfield in the aromatic region in the 1H NMR
spectra and the expected 1,4-regioselectivity was supported 151
by bidimensional spectroscopy [particularly the 3J(C,H)
correlation between protons on the boron-bearing carbon
atom and the unsubstituted carbon of the triazole ring].
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Final deprotection of (+)-pinanediol was accomplished by
transesterification with phenylboronic acid in a biphasic156
system of acetonitrile/n-hexane,[17] to give desired boronic
acids 4a–4e, which were purified by crystallization from
acetonitrile (80–100%).
Table 1. Copper-catalyzed azide–alkyne cycloaddition reaction be-
tween α-azidomethylboronate 2 and several alkynes.
The successful synthesis of these [(1,2,3-triazol-1-yl)-
methyl]boronic acids prompted us to expand our project161
toward chiral compounds and introduce a R2-substituent
(see Figure 1, b). To obtain a homochiral series with natural
amino acids a stereoselective synthesis was required. At first
we focused on triazolyl analogs of acyl-boroLeu that bear
an isobutyl moiety as the R2 group (Scheme 2), a structure166
that is also part of Velcade® (A).
The configuration of the carbon in α position to the
boron is controlled through Matteson’s homologation of
boronic esters, when (+)-pinanediol is used as the chiral
auxiliary agent.[18] Following this procedure, isobutylboron-171
ate 5 was treated with dichloromethyllithium generated in
situ at –100 °C for the insertion of a halogenated and asym-
metrically substituted carbon on the C–B bond. According
to the literature, the use of (+)-pinanediol in 6 induced the
S absolute configuration with high diastereoselectivity (de176
 98%, yield 70%).[19] Subsequent substitution with so-
Scheme 2. Stereoselective synthesis of triazolyl analogs of acyl-boroLeu. (i) LiCHCl2, ZnCl2, THF, –100 °C room temp.; (ii) NaN3,
TBAHS, EtOAc, H2O, room temp.; (iii) alkyne, CuSO4, sodium ascorbate, tBuOH, H2O, room temp.; (iv) phenylboronic acid, HCl,
acetonitrile, n-hexane, room temp.
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dium azide afforded azido boronate 7 (de  98%, yield
97%). With respect to the synthesis of 2, the presence of a
stereogenic center at the reactive site prevents the use of
tetrabutylammonium iodide (TBAI) in favor of non-nucleo- 181
Table 2. Copper-catalyzed azide–alkyne cycloaddition reaction be-
tween chiral α-azidomethylboronates and alkynes.
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philic tetrabutylammonium hydrogensulfate (TBAHS) to
avoid epimerization (30% of undesired epimer was obtained
with TBAI). Click reactions to give 8a–8e under the same
conditions described for the synthesis of 3a–3e performed
equally well without any effect on reaction time (2–16 h, see186
the Experimental Section) or yield (81–97%). Most import-
antly, no effect on the diastereoisomeric composition was
observed in the NMR spectra, which was evaluated through
analyses of the spectra of 8a–8e obtained from an epimeric
mixture of 7. Final deprotection afforded enantiomerically191
pure triazolyl boronic acids 9a–9e (Table 2, Entries 1–5).
The same procedure was replicated for the synthesis of
boroPhe analogs 18a–18e and 19a–19e (Scheme 3), which
bear as the R2 group a benzyl or its meta-carboxy deriva-
tive; the latter of which is a recurring motif in β-lactamase196
inhibitors (Figure 1, C).
Scheme 3. Stereoselective synthesis of triazolyl analogs of acyl-
boroPhe. (i) LiCH2Cl, THF, –80 °C room temp.; (ii) LiCHCl2,
THF, –100 °C room temp.; (iii) NaN3, TBAHS, EtOAc, H2O,
room temp.; (iv) alkyne, CuSO4, sodium ascorbate, tBuOH, H2O,
room temp.; (v) phenylboronic acid, HCl, acetonitrile, n-hexane,
room temp.
(+)-Pinanediol boronates 10 and 11 were subjected to
two consecutive homologation steps: the first with chloro-
methyllithium for methylene insertion to 12 and 13, and the
second with dichloromethyllithium to introduce the halo-201
genated carbon atom (14 and 15).[17] Chlorine substitution
with sodium azide under phase transfer conditions afforded
16 and 17. These key azido intermediates were then sub-
jected to click reaction and deprotection to triazolyl analogs
of acyl-boroPhe 18a–18e and 19a–19e (Table 2, Entries 6–206
15).
The results reported in Table 2 indicate that the described
procedure is reproducible and highly efficient, and affords,
in all cases, the expected triazolylmethylboronic acid in
moderate to good overall yields as pure and stable solids,211
which can be stored for months at +4 °C. The rate of the
CuAAC reaction is not affected by the structure of the
azidomethylboronate, but only by the electronic density of
the alkyne partner: for a given alkyne, reaction times are
www.eurjoc.org © 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 0000, 0–04
consistent for both primary (intermediate 2) and secondary 216
azides (intermediates 16 and 17). Furthermore, for these lat-
ter derivatives cycloaddition reaction proceeds without any
change in the diastereoisomeric composition, to eventually
afford enantiomerically pure triazolylmethylboronic acids.
Conclusions 221
A synthetic procedure for enantiomerically-pure [(1,2,3-
triazol-1-yl)methyl]boronic acids has been developed. This
new scaffold can be obtained through CuAAC reaction be-
tween stereoisomerically pure 1-azidoalkylboronates and
terminal acetylenes, which are catalyzed by copper sulfate, 226
reduced in situ to CuI by sodium ascorbate in a tert-but-
anol/water system. Under these conditions, the proximity of
the reaction center to the boronic group is not detrimental
to the stability of the sp3 C–B bond to copper(I) catalysis,
which further expands the functional group compatibility 231
in CuAAC reaction beyond what is already known. Appli-
cation of powerful click chemistry to boronates enables
many analogs to be synthesized quickly. Given the impor-
tance of α-amidomethylboronic acids as proteases inhibi-
tors, this efficient access to a new bioisosteric scaffold could 236
promote further exploration of boronates as a promising
class of biological active compounds.
Experimental Section
General Methods: All reactions were performed under an argon
atmosphere with oven-dried glassware and dry solvents. Dry THF 241
was obtained by standard methods and freshly distilled under an
argon atmosphere from sodium benzophenone ketyl prior to use.
All of the reagents were used as purchased from commercial suppli-
ers without further purification. The –100 °C bath was prepared by
addition of liquid nitrogen to a pre-cooled (–78 °C) mixture of 1:1 246
ethanol/methanol. Preloaded (0.25 mm) glass supported silica gel
plates (Kieselgel 60, Merck) were used for TLC analysis, and com-
pounds were visualized by exposure to UV light and by dipping
the plates in Ce(SO4)·4H2O (1%), (NH4)6Mo7O24·4H2O (2.5%) in
sulfuric acid (10%) followed by heating on a hot plate. Melting 251
points were measured in open capillary tubes with a Stuart SMP30
Melting Point apparatus. Optical rotations were determined at
+20 °C with a Perkin–Elmer 241 polarimeter and are expressed in
10–1 degcm2g–1. 1H and 13C NMR spectra were recorded with a
Bruker Avance-400 MHz spectrometer. Chemical shifts were cal- 256
ibrated to the residual signals of the deuterated solvent.[20] Multi-
plicity is given as s = singlet, d = doublet, t = triplet, q = quartet, m
= multiplet, br. = broad signal. Two-dimensional NMR techniques
(COSY, HMBC, HSQC) were used to aid in the assignment of
signals in 1H and 13C spectra. In the 13C spectra the signal of the 261
boron-bearing carbon atom tends to be broad, often below the de-
tection limit; however, its resonance was always unambiguously de-
termined by HSQC. The triazole ring carbon signals are often be-
low the detection limit; when possible these were determined by
HSQC and HMBC. High-resolution mass spectra were recorded 266
with an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS.
Elemental analyses were performed with a Carlo Erba Elemental
Analyzer 1110.
General Procedure for CuAAC Between Azidomethylboronates and
Terminal Acetylenes: Azidomethylboronate (1.00 mmol), the se- 271
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lected terminal alkyne (1.50 mmol), copper sulfate solution (50 mg/
mL, 0.05 mmol) and sodium ascorbate (0.20 mmol) were dissolved
in a mixture of tert-butanol and water (1:1; 2.0 mL of each). The
reaction was stirred at room temperature for 2–16 h (as specified
in each case), until the azido boronate disappeared as monitored276
by TLC. The mixture was then partitioned between ethyl acetate
(20 mL), water (10 mL) and saturated NaCl (8 mL), and the aque-
ous phase extracted with ethyl acetate (2 20 mL). The combined
organic phases were washed with brine (15 mL), dried with
Na2SO4, filtered, and concentrated in vacuo, to afford the expected281
[(1,2,3-triazol-1-yl)methyl]boronate.
(+)-Pinanediyl [(4-Ethoxycarbonyl-1,2,3-triazol-1-yl)methyl]boron-
ate (3a): Yellow viscous oil (reaction time 2 h, 97%). [α]D20 = +13.6
(c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.76 (s, 3 H,
pinanyl CH3), 1.03 (d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.21 (s, 3286
H, pinanyl CH3), 1.32 (t, J = 7.0 Hz, 3 H, OCH2CH3), 1.35 (s, 3
H, pinanyl CH3), 1.77–2.30 (m, 5 H, pinanyl protons), 4.20 (s, 2
H, CH2B), 4.29–4.35 (m, 3 H, CHOB, OCH2CH3), 8.19 (s, 1 H,
CHtriaz) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.2, 23.8, 26.4,
26.9, 28.3, 34.9, 35.9 (br., CB), 38.1, 39.2, 51.0, 61.0, 78.9, 87.7,291
128.6, 139.9, 160.9 ppm. HRMS (ESI-TOF) m/z: calcd. for
C16H25BN3O4 [M + H]+ 334.1936; found 334.1938.
(+)-Pinanediyl [(4-Carboxy-1,2,3-triazol-1-yl)methyl]boronate (3b):
White solid (reaction time 2 h, 85%), m.p. 110–113 °C dec. [α]D20 =
+16.6 (c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.82 (s,296
3 H, pinanyl CH3), 1.08 (d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.27
(s, 3 H, pinanyl CH3), 1.42 (s, 3 H, pinanyl CH3), 1.84–2.37 (m, 5
H, pinanyl protons), 4.29 (s, 2 H, CH2B), 4.39 (dd, J = 8.7, 4.4 Hz,
1 H, CHOB), 8.37 (s, 1 H, CHtriaz), 9.57 (s, 1 H, COOH) ppm. 13C
NMR (100 MHz, CDCl3): δ = 24.1, 26.6, 27.1, 28.5, 35.1, 36.3 (br.,301
CB), 38.3, 39.4, 51.1, 79.2, 88.0, 129.5, 139.3, 164.1 ppm. HRMS
(ESI-TOF) m/z: calcd. for C14H21BN3O4 [M + H]+ 306.1622; found
306.1624.
(+)-Pinanediyl [(4-Phenyl-1,2,3-triazol-1-yl)methyl]boronate (3c):
Yellow viscous oil (reaction time 16 h, 99%). [α]D20 = +13.0 (c = 2.2,306
CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.83 (s, 3 H, pinanyl
CH3), 1.15 (d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.28 (s, 3 H, pin-
anyl CH3), 1.43 (s, 3 H, pinanyl CH3), 1.85–2.37 (m, 5 H, pinanyl
protons), 4.24 (s, 2 H, CH2B), 4.39 (dd, J = 8.7, 1.8 Hz, 1 H,
CHOB), 7.29 (t, J = 7.4 Hz, 1 H, Harom), 7.39 (t, J = 7.9 Hz, 2 H,311
Harom), 7.82 (d, J = 7.4 Hz, 2 H, Harom), 7.89 (s, 1 H, CHtriaz) ppm.
13C NMR (100 MHz, CDCl3): δ = 24.0, 26.5, 27.0, 28.5, 35.1, 35.6
(br., CB), 38.2, 39.4, 51.1, 78.9, 87.5, 121.0, 125.7, 127.9, 128.8,
131.0, 147.6 ppm. HRMS (ESI-TOF) m/z: calcd. for C19H25BN3O2
[M + H]+ 338.2038; found 338.2031.316
(+)-Pinanediyl [(4-Thiophen-3-yl-1,2,3-triazol-1-yl)methyl]boronate
(3d): Yellow viscous oil (reaction time 16 h, 92%). [α]D20 = +10.2 (c
= 0.9, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.83 (s, 3 H,
pinanyl CH3), 1.14 (d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.28 (s, 3
H, pinanyl CH3), 1.43 (s, 3 H, pinanyl CH3), 1.85–2.37 (m, 5 H,321
pinanyl protons), 4.23 (s, 2 H, CH2B), 4.38 (dd, J = 8.8, 1.7 Hz, 1
H, CHOB), 7.34 (dd, J = 5.0, 2.9 Hz, 1 H, CHCHS), 7.45 (dd, J
= 5.0, 1.1 Hz, 1 H, CHCHS), 7.64 (dd, J = 2.9, 1.1 Hz, 1 H,
CCHS), 7.79 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CDCl3):
δ = 24.0, 26.6, 27.0, 28.5, 35.1, 35.8 (br., CB), 38.2, 39.4, 51.1, 78.9,326
87.6, 120.8, 120.9, 126.0, 126.1, 132.3, 143.8 ppm. HRMS (ESI-
TOF) m/z: calcd. for C17H23BN3O2S [M + H]+ 344.1602; found
344.1610.
(+)-Pinanediyl [(4-Phenoxymethyl-1,2,3-triazol-1-yl)methyl]boron-
ate (3e): Yellow viscous oil (reaction time 8 h, 97%). [α]D20 = +13.1331
(c = 2.1, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.85 (s, 3 H,
pinanyl CH3), 1.13 (d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.30 (s, 3
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H, pinanyl CH3), 1.43 (s, 3 H, pinanyl CH3), 1.85–2.39 (m, 5 H,
pinanyl protons), 4.22 (s, 2 H, CH2B), 4.39 (dd, J = 8.8, 1.8 Hz, 1
H, CHOB), 5.21 (s, 2 H, OCH2), 6.96 (t, J = 7.3 Hz, 1 H, Harom), 336
7.00 (d, J = 8.7 Hz, 2 H, Harom), 7.28 (dd, J = 8.7, 7.3 Hz, 2 H,
Harom), 7.77 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CDCl3):
δ = 24.0, 26.5, 27.0, 28.5, 35.1, 35.8 (br., CB), 38.2, 39.4, 51.1, 62.1,
78.9, 87.5, 114.9, 121.2, 124.1, 129.5, 143.9, 158.4 ppm. HRMS
(ESI-TOF) m/z: calcd. for C20H27BN3O3 [M + H]+ 368.2144; found 341
368.2139.
General Procedure for Deprotection of Pinanediyl Boronates
Through Transesterification: To a solution of [(1,2,3-triazol-1-yl)
methyl]boronate (0.50 mmol) in CH3CN (3 mL), HCl (3 m aqueous
solution, 1.50 mmol), phenylboronic acid (0.47 mmol), and n-hex- 346
ane (3 mL) were sequentially added and the resulting biphasic solu-
tion was vigorously stirred. After 30 min the n-hexane layer, which
contained the pinanediol phenylboronate, was removed and fresh
n-hexane (3 mL) was added. This last step was repeated several
times until a TLC analysis of the n-hexane layer revealed no phen- 351
ylboronate production (total reaction time 3 h). The acetonitrile
phase was then concentrated and the crude product was recrys-
tallized from acetonitrile to afford [(1,2,3-triazol-1-yl)methyl]-
boronic acid.
The enantiomeric purity of chiral boronic acids was checked by 356
reconversion into their pinanediol esters. Final compounds 9a–9e,
18a–18e, and 19a–19e were allowed to react with an equimolar
amount of (+)-pinanediol in anhydrous THF: the NMR spectra of
the crude products displayed the presence of a single diastereoiso-
mer, which proves that no epimerization occurred during the trans- 361
esterification reaction.
[(4-Ethoxycarbonyl-1,2,3-triazol-1-yl)methyl]boronic Acid (4a):
White solid (80%), m.p. 123–125 °C dec. 1H NMR (400 MHz,
CD3OD): δ = 1.38 (t, J = 7.1 Hz, 3 H, OCH2CH3), 4.27 (s, 2 H,
CH2B), 4.38 (q, J = 7.1 Hz, 2 H, OCH2CH3), 8.38 (s, 1 H, 366
CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 14.6, 39.3 (br.,
CB), 62.1, 130.5, 140.4 ppm, COOEt not seen. HRMS (ESI-TOF)
m/z: calcd. for C6H11BN3O4 [M + H]+ 200.0838; found 200.0840.
[(4-Carboxy-1,2,3-triazol-1-yl)methyl]boronic Acid (4b): White solid
(80%), m.p. 236–240 °C dec. 1H NMR (400 MHz, CD3OD): δ = 371
4.26 (s, 2 H, CH2B), 8.39 (s, 1 H, CHtriaz) ppm. 13C NMR
(100 MHz, CD3OD): δ = 39.9 (br., CB), 130.7, 140.6, 163.3 ppm.
HRMS (ESI-TOF) m/z: calcd. for C4H7BN3O4 [M + H]+ 172.0525;
found 172.0518.
[(4-Phenyl-1,2,3-triazol-1-yl)methyl]boronic Acid (4c): Grey solid 376
(98%), m.p. 122–124 °C dec. 1H NMR (400 MHz, CD3OD): δ =
4.48 (s, 2 H, CH2B), 7.56–7.60 (m, 3 H, Harom), 7.83 (dd, J = 7.8,
1.7 Hz, 2 H, Harom), 8.78 (s, 1 H, CHtriaz) ppm. 13C NMR
(100 MHz, CD3OD): δ = 42.6 (br., CB), 126.0, 126.8, 127.6, 130.7,
131.9, 144.7 ppm. HRMS (ESI-TOF) m/z: calcd. for C9H11BN3O2 381
[M + H]+ 204.0941; found 204.0940.
[(4-Thiophen-3-yl-1,2,3-triazol-1-yl)methyl]boronic Acid (4d): White
solid (100%), m.p. 170–172 °C dec. 1H NMR (400 MHz, CD3OD):
δ = 4.47 (s, 2 H, CH2B), 7.55 (dd, J = 5.1, 1.1 Hz, 1 H, CHCHS),
7.69 (dd, J = 5.1, 2.8 Hz, 1 H, CHCHS), 8.08 (dd, J = 2.8, 1.1 Hz, 386
1 H, CCHS), 8.70 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz,
CD3OD): δ = 42.7 (br., CB), 126.4, 126.5, 126.6, 127.0, 129.6,
140.4 ppm. HRMS (ESI-TOF) m/z: calcd. for C7H9BN3O2S [M +
H]+ 210.0504; found 210.0498.
[(4-Phenoxymethyl-1,2,3-triazol-1-yl)methyl]boronic Acid (4e): 391
White solid (100%), m.p. 128–131 °C dec. 1H NMR (400 MHz,
CD3OD): δ = 4.44 (s, 2 H, CH2B), 5.33 (s, 2 H, OCH2), 7.01 (t, J
= 7.4 Hz, 1 H, Harom), 7.05 (dd, J = 8.7, 0.8 Hz, 2 H, Harom), 7.32
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(dd, J = 8.7, 7.4 Hz, 2 H, Harom), 8.48 (s, 1 H, CHtriaz) ppm. 13C
NMR (100 MHz, CD3OD): δ = 42.5 (br., CB), 60.4, 116.0, 123.1,396
129.0, 130.8, 141.5, 159.0 ppm. HRMS (ESI-TOF) m/z: calcd. for
C10H13BN3O3 [M + H]+ 234.1046; found 234.1048.
(+)-Pinanediyl [(1R)-1-Azido-3-methylbutyl]boronate (7): To a solu-
tion of 6[21] (800 mg, 2.81 mmol) in ethyl acetate (10 mL), sodium
azide (1.83 g, 28.1 mmol), tetrabutylammonium hydrogensulfate401
(475 mg, 1.40 mmol), and water (24 mL) were added and the sys-
tem was vigorously stirred at room temperature overnight. The
mixture was then diluted with saturated ammonium chloride/water
(1:1, 40 mL) and extracted twice with light petroleum (60 mL,
30 mL). The combined organic fractions were washed again with406
saturated ammonium chloride/water (1:1, 20 mL), dried with
Na2SO4, and filtered. Removal of solvent in vacuo afforded 7 as a
colorless oil (794 mg, 97% yield). [α]D20 = –7.13 (c = 1.7, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.83 (s, 3 H, pinanyl CH3), 0.92
[d, J = 6.6 Hz, 3 H, CH(CH3)2], 0.93 [d, J = 6.6 Hz, 3 H, CH(CH3)2],411
1.09 (d, J = 11.0 Hz, 1 H, pinanyl Hendo), 1.28 (s, 3 H, pinanyl
CH3), 1.40 (s, 3 H, pinanyl CH3), 1.45 (ddd, J = 14.0, 8.5, 5.4 Hz,
1 H, BCHCH2), 1.63 (ddd, J = 14.0, 10.0, 5.4 Hz, 1 H, BCHCH2),
1.76–1.83 [m, 1 H, CH(CH3)2], 1.85–2.37 (m, 5 H, pinanyl pro-
tons), 3.11 (dd, J = 10.0, 5.4 Hz, 1 H, BCH), 4.34 (dd, J = 8.8,416
1.8 Hz, 1 H, CHOB) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.7,
23.1, 24.0, 25.7, 26.6, 27.1, 28.6, 35.4, 38.2, 39.3, 39.5, 46.4 (br.,
CB), 51.2, 78.5, 86.9 ppm. C15H26BN3O2 (291.20): calcd. C 61.87,
H 9.00, N 14.43; found C 61.66, H 9.21, N 14.29.
(+)-Pinanediyl [(1R)-1-(4-Ethoxycarbonyl-1,2,3-triazol-1-yl)-3-421
methylbutyl]boronate (8a): According to the general procedure re-
ported above, CuAAC reaction between azido boronate 7 and ethyl
propiolate (reaction time 2 h) afforded 8a as a yellow viscous oil
(reaction time 2 h, 89%). [α]D20 = +25.0 (c = 0.9, CHCl3). 1H NMR
(400 MHz, CDCl3): δ = 0.80 (s, 3 H, pinanyl CH3), 0.83 [d, J =426
6.6 Hz, 3 H, CH(CH3)2], 0.90 [d, J = 6.5 Hz, 3 H, CH(CH3)2], 1.03
(d, J = 11.1 Hz, 1 H, pinanyl Hendo), 1.25 (s, 3 H, pinanyl CH3),
1.28–1.34 [m, 1 H, CH(CH3)2], 1.38 (s, 3 H, pinanyl CH3), 1.38 (t,
J = 7.0 Hz, 3 H, OCH2CH3), 1.71–2.34 (m, 7 H, pinanyl protons,
BCHCH2), 4.32 (d, J = 8.7 Hz, 1 H, CHOB), 4.39 (q, J = 7.0 Hz,431
2 H, OCH2CH3), 4.60 (dd, J = 10.3, 5.5 Hz, 1 H, BCH), 8.16 (s, 1
H, CHtriaz) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.4, 21.4,
22.8, 24.0, 25.0, 26.5, 27.0, 28.5, 35.2, 38.2, 39.4, 41.4, 47.1 (br.,
CB), 51.1, 61.2, 78.9, 87.6, 127.5, 140.1, 161.2 ppm. HRMS (ESI-
TOF) m/z: calcd. for C20H33BN3O4 [M + H]+ 390.2562; found436
390.2563.
(+)-Pinanediyl [(1R)-1-(4-Carboxy-1,2,3-triazol-1-yl)-3-methylbut-
yl]boronate (8b): Yellow viscous oil (reaction time 2 h, 91%). [α]D20
= +19.5 (c = 1.4, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.82
(s, 3 H, pinanyl CH3), 0.86 [d, J = 6.4 Hz, 3 H, CH(CH3)2], 0.94441
[d, J = 6.3 Hz, 3 H, CH(CH3)2], 1.04 (d, J = 11.1 Hz, 1 H, pinanyl
Hendo), 1.28 (s, 3 H, pinanyl CH3), 1.32–1.37 [m, 1 H, CH(CH3)2],
1.41 (s, 3 H, pinanyl CH3), 1.83–2.37 (m, 7 H, pinanyl protons,
BCHCH2), 4.35 (dd, J = 8.7, 1.5 Hz, 1 H, CHOB), 4.65 (dd, J =
10.3, 5.5 Hz, 1 H, BCH), 8.33 (s, 1 H, CHtriaz), 8.74 (br., 1 H,446
COOH) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.4, 22.9, 24.0,
25.1, 26.5, 27.1, 28.5, 35.2, 38.3, 39.4, 41.4, 47.7 (br., CB), 51.1,
79.0, 87.8, 128.3, 139.4, 164.0 ppm. HRMS (ESI-TOF) m/z: calcd.
for C18H29BN3O4 [M + H]+ 362.2249; found 362.2254.
(+)-Pinanediyl [(1R)-3-Methyl-1-(4-phenyl-1,2,3-triazol-1-yl)butyl]-451
boronate (8c): Yellow viscous oil (reaction time 16 h, 81%). [α]D20 =
+11.8 (c = 1.8, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.84 (s,
3 H, pinanyl CH3), 0.88 [d, J = 6.6 Hz, 3 H, CH(CH3)2], 0.97 [d,
J = 6.5 Hz, 3 H, CH(CH3)2], 1.13 (d, J = 11.0 Hz, 1 H, pinanyl
Hendo), 1.29 (s, 3 H, pinanyl CH3), 1.33–1.41 [m, 1 H, CH(CH3)2],456
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1.42 (s, 3 H, pinanyl CH3), 1.73–2.38 (m, 7 H, pinanyl protons,
BCHCH2), 4.37 (dd, J = 8.7, 1.6 Hz, 1 H, CHOB), 4.60 (dd, J =
10.5, 5.6 Hz, 1 H, BCH), 7.31 (t, J = 7.5 Hz, 1 H, Harom), 7.41 (t,
J = 7.5 Hz, 2 H, Harom), 7.85 (d, J = 7.5 Hz, 2 H, Harom), 7.86 (s,
1 H, CHtriaz) ppm. 13C NMR (100 MHz, CDCl3): δ = 21.6, 23.0, 461
24.1, 25.2, 26.6, 27.1, 28.6, 35.3, 38.3, 39.5, 41.6, 46.5 (br., CB),
51.2, 78.9, 87.4, 119.7, 125.8, 128.0, 128.9, 131.2, 147.5 ppm.
HRMS (ESI-TOF) m/z: calcd. for C23H33BN3O2 [M + H]+
394.2665; found 394.2671.
(+)-Pinanediyl [(1R)-3-Methyl-1-(4-thiophen-3-yl-1,2,3-triazol-1-yl)- 466
butyl]boronate (8d): Yellow viscous oil (reaction time 16 h, 85%).
[α]D20 = +13.1 (c = 1.6, CHCl3). 1H NMR (400 MHz, CDCl3): δ =
0.84 (s, 3 H, pinanyl CH3), 0.87 [d, J = 6.6 Hz, 3 H, CH(CH3)2],
0.96 [d, J = 6.5 Hz, 3 H, CH(CH3)2], 1.12 (d, J = 11.0 Hz, 1 H,
pinanyl Hendo), 1.29 (s, 3 H, pinanyl CH3), 1.33–1.38 [m, 1 H, 471
CH(CH3)2], 1.42 (s, 3 H, pinanyl CH3), 1.72–2.37 (m, 7 H, pinanyl
protons, BCHCH2), 4.36 (d, J = 7.2 Hz, 1 H, CHOB), 4.58 (dd, J
= 10.5, 5.5 Hz, 1 H, BCH), 7.36 (dd, J = 4.8, 2.8 Hz, 1 H,
CHCHS), 7.48 (d, J = 4.8 Hz, 1 H, CHCHS), 7.67 (d, J = 2.8 Hz,
1 H, CCHS), 7.75 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, 476
CDCl3): δ = 21.5, 23.0, 24.0, 25.1, 26.5, 27.1, 28.6, 35.3, 38.3, 39.5,
41.6, 46.6 (br., CB), 51.2, 78.8, 87.4, 119.5, 120.8, 126.0, 126.1,
132.4, 143.7 ppm. HRMS (ESI-TOF) m/z: calcd. for
C21H31BN3O2S [M + H]+ 400.2228; found 400.2225.
(+)-Pinanediyl [(1R)-3-Methyl-1-(4-phenoxymethyl-3-yl-1,2,3-tri- 481
azol-1-yl)butyl]boronate (8e): Yellow viscous oil (reaction time 8 h,
97%). [α]D20 = +17.0 (c = 1.3, CHCl3). 1H NMR (400 MHz, CDCl3):
δ = 0.83 (s, 3 H, pinanyl CH3), 0.85 [d, J = 6.6 Hz, 3 H, CH(CH3)
2], 0.94 [d, J = 6.5 Hz, 3 H, CH(CH3)2], 1.07 (d, J = 11.0 Hz, 1 H,
pinanyl Hendo), 1.28 (s, 3 H, pinanyl CH3), 1.30–1.36 [m, 1 H, 486
CH(CH3)2], 1.40 (s, 3 H, pinanyl CH3), 1.70–2.36 (m, 7 H, pinanyl
protons, BCHCH2), 4.34 (dd, J = 8.7, 1.8 Hz, 1 H, CHOB), 4.55
(dd, J = 10.2, 5.8 Hz, 1 H, BCH), 5.21 (s, 2 H, OCH2), 6.96 (t, J
= 7.4 Hz, 1 H, Harom), 6.99 (d, J = 7.9 Hz, 2 H, Harom), 7.28 (t, J
= 7.6 Hz, 2 H, Harom), 7.69 (s, 1 H, CHtriaz) ppm. 13C NMR 491
(100 MHz, CDCl3): δ = 21.6, 22.9, 24.0, 25.1, 26.5, 27.1, 28.5, 35.2,
38.3, 39.4, 41.5, 46.8 (br., CB), 51.2, 62.4, 78.8, 87.4, 115.0, 121.2,
122.8, 129.5, 144.0, 158.5 ppm. HRMS (ESI-TOF) m/z: calcd. for
C24H35BN3O3 [M + H]+ 424.2770; found 424.2788.
[(1R)-1-(4-Ethoxycarbonyl-1,2,3-triazol-1-yl)-3-methylbutyl]boronic 496
Acid (9a): Following the general procedure reported above, pinane-
diol removal from 8a by transesterification reaction afforded 9a as
a white solid (76% yield), m.p. 115–117 °C dec. [α]D20 = +9.2 (c =
0.8, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 0.84 [d, J =
6.5 Hz, 3 H, CH(CH3)2], 0.92 [d, J = 6.4 Hz, 3 H, CH(CH3)2], 501
1.14–1.24 [m, 1 H, CH(CH3)2], 1.37 (t, J = 6.8 Hz, 3 H,
OCH2CH3), 1.70–1.76 (m, 1 H, BCHCH2), 1.90–1.97 (m, 1 H,
BCHCH2), 4.38 (q, J = 6.8 Hz, 2 H, OCH2CH3), 4.53 (dd, J =
10.8, 3.8 Hz, 1 H, BCH), 8.54 (s, 1 H, CHtriaz) ppm. 13C NMR
(100 MHz, CD3OD): δ = 14.5, 21.4, 23.3, 26.2, 41.7, 51.3 (br., CB), 506
62.1, 129.4, 140.5, 162.2 ppm. HRMS (ESI-TOF) m/z: calcd. for
C10H19BN3O4 [M + H]+ 256.1465; found 256.1468.
[(1R)-1-(4-Carboxy-1,2,3-triazol-1-yl)-3-methylbutyl]boronic Acid
(9b): White solid (95%), m.p. 123–127 °C dec. [α]D20 = +4.5 (c = 0.4,
CH3OH). 1H NMR (400 MHz, CD3OD): δ = 0.86 [d, J = 6.6 Hz, 511
3 H, CH(CH3)2], 0.94 [d, J = 6.5 Hz, 3 H, CH(CH3)2], 1.20–1.27
[m, 1 H, CH(CH3)2], 1.72 (ddd, J = 14.3, 8.9, 4.5 Hz, 1 H,
BCHCH2), 1.94 (ddd, J = 14.3, 11.2, 4.7 Hz, 1 H, BCHCH2), 4.58
(dd, J = 11.2, 4.5 Hz, 1 H, BCH), 8.51 (s, 1 H, CHtriaz) ppm. 13C
NMR (100 MHz, CD3OD): δ = 21.4, 23.3, 26.3, 41.7, 51.1 (br., 516
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CB), 129.8, 141.0, 163.1 ppm. HRMS (ESI-TOF) m/z: calcd. for
C8H15BN3O4 [M + H]+ 228.1152; found 228.1148.
[(1R)-3-Methyl-1-(4-phenyl-1,2,3-triazol-1-yl)butyl]boronic Acid
(9c): Cream-colored solid (80%), m.p. 127–132 °C dec. [α]D20 = +8.0
(c = 0.5, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 0.92 [d, J521
= 6.6 Hz, 3 H, CH(CH3)2], 0.98 [d, J = 6.5 Hz, 3 H, CH(CH3)2],
1.31–1.38 [m, 1 H, CH(CH3)2], 1.84 (ddd, J = 14.6, 9.3, 4.1 Hz, 1
H, BCHCH2), 2.14 (ddd, J = 14.6, 11.5, 4.5 Hz, 1 H, BCHCH2),
4.69 (dd, J = 11.5, 4.1 Hz, 1 H, BCH), 7.51–7.58 (m, 3 H, Harom),
7.86 (d, J = 6.8 Hz, 2 H, Harom), 8.94 (s, 1 H, CHtriaz) ppm. 13C526
NMR (100 MHz, CD3OD): δ = 21.3, 23.3, 26.3, 40.8, 54.6 (br.,
CB), 125.7, 126.1, 127.6, 130.7, 131.9, 145.0 ppm. HRMS (ESI-
TOF) m/z: calcd. for C13H19BN3O2 [M + H]+ 260.1567; found
260.1563.
[(1R)-3-Methyl-1-(4-thiophen-3-yl-1,2,3-triazol-1-yl)butyl]boronic531
Acid (9d): Cream-colored solid (92%), m.p. 130–132 °C dec. [α]D20
= +6.2 (c = 0.6, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 0.91
[d, J = 6.6 Hz, 3 H, CH(CH3)2], 0.98 [d, J = 6.6 Hz, 3 H, CH(CH3)
2], 1.26–1.38 [m, 1 H, CH(CH3)2], 1.82 (ddd, J = 14.6, 9.3, 4.3 Hz,
1 H, BCHCH2), 2.10 (ddd, J = 14.6, 11.5, 4.6 Hz, 1 H, BCHCH2),536
4.66 (dd, J = 11.5, 4.3 Hz, 1 H, BCH), 7.56 (d, J = 4.9 Hz, 1 H,
CHCHS), 7.66 (dd, J = 5.1, 2.8 Hz, 1 H, CHCHS), 8.04 (d, J =
2.0 Hz, 1 H, CCHS), 8.78 (s, 1 H, CH tr iaz) ppm. 13C NMR
(100 MHz, CD3OD): δ = 21.3, 23.3, 26.3, 40.9, 54.3 (br., CB),
125.1, 126.3, 126.5, 127.3, 129.3, 141.3 ppm. HRMS (ESI-TOF)541
m/z: calcd. for C11H17BN3O2S [M + H]+ 266.1131; found 266.1137.
[(1R)-3-Methyl-1-(4-phenoxymethyl-3-yl-1,2,3-triazol-1-yl)butyl]-
boronic Acid (9e): White solid (77%), m.p. 118–123 °C dec. [α]D20 =
+2.9 (c = 1.2, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 0.87
[d, J = 6.6 Hz, 3 H, CH(CH3)2], 0.95 [d, J = 6.5 Hz, 3 H, CH(CH3)546
2], 1.20–1.29 [m, 1 H, CH(CH3)2], 1.73 (ddd, J = 14.5, 9.1, 4.5 Hz,
1 H, BCHCH2), 1.97 (ddd, J = 14.5, 11.3, 4.6 Hz, 1 H, BCHCH2),
4.64 (dd, J = 11.3, 4.5 Hz, 1 H, BCH), 5.24 (s, 2 H, OCH2), 6.98
(tt, J = 7.4, 1.0 Hz, 1 H, Harom), 7.02 (d, J = 8.7, 1.0 Hz, 2 H,
Harom), 7.30 (dd, J = 8.7, 7.4 Hz, 2 H, Harom), 8.30 (s, 1 H,551
CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 21.4, 23.3, 26.3,
41.4, 51.9 (br., CB), 61.4, 116.1, 122.7, 126.6, 130.6, 143.3,
159.3 ppm. HRMS (ESI-TOF) m/z: calcd. for C14H21BN3O3 [M +
H]+ 290.1673; found 290.1673.
(+)-Pinanediyl [(1R)-1-Azido-2-phenylethyl]boronate (16): Starting556
from 14[17] and following the procedure described for the synthesis
of 7, compound 16 was recovered as a yellowish oil (94%). [α]D20 =
+8.7 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3): δ = 0.83 (s,
3 H, pinanyl CH3), 0.98 (d, J = 11.0 Hz, 1 H, pinanyl Hendo), 1.29
(s, 3 H, pinanyl CH3), 1.38 (s, 3 H, pinanyl CH3), 1.85–2.37 (m, 5561
H, pinanyl protons), 2.95 (dd, J = 14.0, 9.0 Hz, 1 H, BCHCH2),
3.03 (dd, J = 14.0, 5.7 Hz, 1 H, BCHCH2), 3.38 (dd, J = 9.0,
5.7 Hz, 1 H, BCH), 4.33 (dd, J = 8.7, 1.7 Hz, 1 H, CHOB), 7.19–
7.32 (m, 5 H, Harom) ppm. 13C NMR (100 MHz, CDCl3): δ = 24.1,
26.5, 27.1, 28.6, 35.3, 36.9, 38.3, 39.5, 49.8 (br., CB), 51.2, 78.7,566
87.1, 126.8, 128.6, 129.3, 138.8 ppm. C18H24BN3O2 (325.22): calcd.
C 66.48, H 7.44, N 12.92; found C 66.25, H 7.68, N 12.72.
(+)-Pinanediyl [(1R)-1-Azido-2-(3-tert-butoxycarbonylphenyl)ethyl]-
boronate (17): Starting from 15[17] and following the procedure de-
scribed for the synthesis of 7, compound 17 was recovered as a571
yellowish oil (97%). [α]D20 = +11.9 (c = 1.8, CHCl3). 1H NMR
(400 MHz, CDCl3): δ = 0.82 (s, 3 H, pinanyl CH3), 0.93 (d, J =
11.0 Hz, 1 H, pinanyl Hendo), 1.27 (s, 3 H, pinanyl CH3), 1.37 (s, 3
H, pinanyl CH3), 1.59 (s, 9 H, tBu), 1.86–2.38 (m, 5 H, pinanyl
protons), 2.99 (dd, J = 13.9, 8.5 Hz, 1 H, BCHCH2), 3.05 (dd, J =576
13.9, 6.0 Hz, 1 H, BCHCH2), 3.39 (dd, J = 8.5, 6.0 Hz, 1 H, BCH),
4.34 (d, J = 7.6 Hz, 1 H, CHOB), 7.34 (t, J = 7.7 Hz, 1 H, Harom),
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7.44 (d, J = 7.7 Hz, 1 H, Harom), 7.86 (d, J = 7.7 Hz, 1 H, Harom),
7.89 (s, 1 H, Harom) ppm. 13C NMR (100 MHz, CDCl3): δ = 24.0,
26.4, 27.1, 28.3, 28.5, 35.2, 36.7, 38.2, 39.5, 49.5 (br., CB), 51.1, 581
78.7, 81.0, 87.1, 128.0, 128.4, 130.2, 132.3, 133.4, 138.8, 165.7 ppm.
C23H32BN3O4 (425.33): calcd. C 64.95, H 7.58, N 9.88; found C
65.18, H 7.81, N 9.64.
[(1R)-1-(4-Ethoxycarbonyl-1,2,3-triazol-1-yl)-2-phenylethyl]boronic
Acid (18a): According to the general procedure reported above, 586
CuAAC reaction between azido boronate 16 and ethyl propiolate
(reaction time 2 h) followed by deprotection of pinanediol boronate
ester through transesterification reaction afforded 18a as a white
solid (75% overall yield), m.p. 147–149 °C dec. [α]D20 = –53.7 (c =
1.1, CH3OH). 1H NMR (400 MHz, CD3OD): δ = 1.34 (t, J = 591
7.1 Hz, 3 H, OCH2CH3), 3.20 (dd, J = 14.0, 9.9 Hz, 1 H,
BCHCH2), 3.25–3.31 (m, 1 H, BCHCH2 and CD3OD), 4.33 (q, J
= 7.1 Hz, 2 H, OCH2CH3), 4.62 (dd, J = 9.9, 4.9 Hz, 1 H, BCH),
6.97 (d, J = 7.0 Hz, 2 H, Harom), 7.14–7.20 (m, 3 H, Harom), 8.16
(s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 14.5, 596
39.2, 55.4 (br., CB), 62.2, 127.7, 129.5, 129.7, 130.4, 139.3,
162.3 ppm, C-4 triazole ring not seen. HRMS (ESI-TOF) m/z:
calcd. for C13H17BN3O4 [M + H]+ 290.1309; found 290.1295.
[(1R)-1-(4-Carboxy-1,2,3-triazol-1-yl)-2-phenylethyl]boronic Acid
(18b): White solid (reaction time 2 h, 85% overall yield), m.p. 120– 601
122 °C dec. [α]D20 = –43.4 (c = 1.0, CH3OH). 1H NMR (400 MHz,
CD3OD): δ = 3.18 (dd, J = 14.0, 10.0 Hz, 1 H, BCHCH2), 3.27–
3.32 (m, 1 H, BCHCH2 and CD3OD), 4.68 (dd, J = 10.0, 5.6 Hz,
1 H, BCH), 7.00 (d, J = 6.6 Hz, 2 H, Harom), 7.14–7.22 (m, 3 H,
Harom), 8.15 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): 606
δ = 39.3, 54.5 (br., CB), 127.8, 129.5, 129.8, 130.3, 139.2, 140.4,
163.2 ppm. HRMS (ESI-TOF) m/z: calcd. for C11H13BN3O4 [M +
H]+ 262.0996; found 262.0994.
[(1R)-1-(4-Phenyl-1,2,3-triazol-1-yl)-2-phenylethyl]boronic Acid
(18c):White solid (reaction time 16 h, 70% overall yield), m.p. 151– 611
153 °C dec. [α]D20 = –62.3 (c = 1.3, CH3OH). 1H NMR (400 MHz,
CD3OD): δ = 3.25–3.31 (m, 1 H, BCHCH2 and CD3OD), 3.39 (dd,
J = 14.1, 5.7 Hz, 1 H, BCHCH2), 4.84 (dd, J = 10.0, 5.7 Hz, 1 H,
BCH), 7.12 (d, J = 6.9 Hz, 2 H, Harom), 7.16–7.25 (m, 3 H, Harom),
7.44–7.52 (m, 3 H, Harom), 7.73 (d, J = 6.7 Hz, 2 H, Harom), 8.51 616
(s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 38.8,
56.3 (br., CB), 125.1, 127.2, 127.8, 128.1, 129.7, 129.9, 130.4, 131.1,
138.8, 145.9 ppm. HRMS (ESI-TOF) m/z: calcd. for C16H17BN3O2
[M + H]+ 294.1411; found 294.1423.
[(1R)-2-Phenyl-1-(4-thiophen-3-yl-1,2,3-triazol-1-yl)ethyl]boronic 621
Acid (18d): Cream-colored solid (reaction time 16 h, 80% overall
yield), m.p. 141–143 °C dec. [α]D20 = –67.3 (c = 1.1, CH3OH). 1H
NMR (400 MHz, CD3OD): δ = 3.25–3.32 (m, 1 H, BCHCH2 and
CD3OD), 3.40 (dd, J = 14.2, 5.7 Hz, 1 H, BCHCH2), 4.87 (dd, J
= 10.6, 5.7 Hz, 1 H, BCH), 7.13 (d, J = 6.9 Hz, 2 H, Harom), 7.17– 626
7.25 (m, 3 H, Harom), 7.47 (d, J = 5.0 Hz, 1 H, Harom), 7.63 (dd, J
= 5.0, 2.8 Hz, 1 H, Harom), 7.94 (d, J = 1.9 Hz, 1 H, Harom), 8.57
(s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 38.7,
56.7 (br., CB), 125.3, 126.0, 126.5, 127.5, 128.1, 129.2, 129.7, 129.8,
1 3 8 . 6 , 1 4 1 . 5 ppm . HRMS (ES I -TOF ) m / z : c a l c d . fo r 631
C14H15BN3O2S [M + H]+ 300.0975; found 300.0987.
[(1R)-2-Phenyl-1-(4-phenoxymethyl-1,2,3-triazol-1-yl)ethyl]boronic
Acid (18e):White solid (reaction time 16 h, 79% overall yield), m.p.
113–115 °C dec. [α]D20 = –50.1 (c = 0.8, CH3OH). 1H NMR
(400 MHz, CD3OD): δ = 3.13 (dd, J = 14.0, 9.8 Hz, 1 H, 636
BCHCH2), 3.24–3.32 (m, 1 H, BCHCH2 and CD3OD), 4.67 (dd,
J = 9.8, 5.8 Hz, 1 H, BCH), 5.10 (s, 2 H, OCH2), 6.93–6.97 (m, 5
H, Harom), 7.14–7.16 (m, 3 H, Harom), 7.25–7.29 (m, 2 H, Harom),
7.92 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ =
Job/Unit: O43408 /KAP1 Date: 18-12-14 19:29:05 Pages: 10
C. Romagnoli, E. Caselli, F. PratiFULL PAPER
39.4, 53.9 (br., CB), 62.1, 116.0, 122.3, 127.7, 129.5, 129.76, 129.85,641
130.5, 139.4, 159.6 ppm, C-4 triazole ring not seen. HRMS (ESI-
TOF) m/z: calcd. for C17H19BN3O3 [M + H]+ 324.1517; found
324.1513.
[(1R)-1-(4-Carboxy-1,2,3-triazol-1-yl)-2-(3-carboxyphenyl)ethyl]
boronic Acid (19a): According to the general procedure reported646
above, the product of the CuAAC reaction between azido boronate
17 and ethyl propiolate (reaction time 2 h) was firstly subjected
to tert-butyl group removal (trifluoroacetic anhydride 25% v/v in
CH2Cl2, 2 mL, room temp., 5 h) followed by deprotection of pin-
anediol boronate ester through transesterification reaction afforded651
19a as a white solid (64% overall yield), m.p. 157–159 °C dec. [α]
D
20 = –54.9 (c = 1.2, CH3OH). 1H NMR (400 MHz, CD3OD): δ =
1.35 (t, J = 7.1 Hz, 3 H, OCH2CH3), 3.24 (dd, J = 14.0, 10.0 Hz,
1 H, BCHCH2), 3.34 (dd, J = 14.0, 5.2 Hz, 1 H, BCHCH2), 4.34
(q, J = 7.1 Hz, 2 H, OCH2CH3), 4.75 (m, 1 H, BCH), 7.26 (d, J =656
7.6 Hz, 1 H, Harom), 7.33 (t, J = 7.6 Hz, 1 H, Harom), 7.69 (s, 1 H,
Harom), 7.85 (d, J = 7.6 Hz, 1 H, Harom), 8.23 (s, 1 H, CHtriaz) ppm.
13C NMR (100 MHz, CD3OD): δ = 14.5, 39.1, 54.4 (br., CB), 62.1,
128.5, 129.2, 129.6, 130.3, 131.2, 134.5, 139.9, 162.1, 169.4 ppm, C-
4 triazole ring not seen. HRMS (ESI-TOF) m/z: calcd. for661
C14H17BN3O6 [M + H]+ 334.1204; found 334.1208.
[(1R)-2-(3-Carboxyphenyl)-1-(4-ethoxycarbonyl-1,2,3-triazol-1-yl)-
ethyl]boronic Acid (19b):White solid (reaction time 2 h, 55% overall
yield), m.p. 108–110 °C dec. [α]D20 = –49.2 (c = 1.5, CH3OH). 1H
NMR (400 MHz, CD3OD): δ = 3.26 (dd, J = 14.0, 10.1 Hz, 1 H,666
BCHCH2), 3.31–3.41 (m, 1 H, BCHCH2 and CD3OD), 4.71 (br.,
1 H, BCH), 7.22 (d, J = 7.7 Hz, 1 H, Harom), 7.32 (t, J = 7.7 Hz,
1 H, Harom), 7.71 (s, 1 H, Harom), 7.84 (d, J = 7.7 Hz, 1 H, Harom),
8.18 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ =
39.1, 53.9 (br., CB), 128.5, 129.2, 129.6, 131.2, 132.2, 134.6, 139.9,671
140.8, 163.5, 169.6 ppm. HRMS (ESI-TOF) m/z: calcd. for
C12H11BN3O6 [M – H]– 304.0749; found 304.0739.
[(1R)-2-(3-Carboxyphenyl)-1-(4-phenyl-1,2,3-triazol-1-yl)ethyl]-
boronic Acid (19c): White solid (reaction time 16 h, 79% overall
yield), m.p. 88–90 °C dec. [α]D20 = –70.0 (c = 1.0, CH3OH). 1H676
NMR (400 MHz, CD3OD): δ = 3.26–3.32 (m, 1 H, BCHCH2 and
CD3OD), 3.39 (dd, J = 14.1, 5.8 Hz, 1 H, BCHCH2), 4.74 (dd, J
= 9.9, 5.8 Hz, 1 H, BCH), 7.29–7.44 (m, 5 H, Harom), 7.71 (d, J =
7.4 Hz, 2 H, Harom), 7.76 (s, 1 H, Harom), 7.85 (d, J = 7.2 Hz, 1 H,
Harom), 8.17 (s, 1 H, CHtriaz) ppm. 13C NMR (100 MHz, CD3OD):681
δ = 39.1, 54.0 (br., CB), 123.6, 126.8, 129.2, 129.7, 130.00, 130.06,
131.2, 132.2, 134.7, 140.0, 147.1, 169.6 ppm, C-4 triazole ring not
seen. HRMS (ESI-TOF) m/z: calcd. for C17H17BN3O4 [M + H]+
338.1310; found 338.1310.
[(1R)-2-(3-Carboxyphenyl)1-(4-thiophen-3-yl-1,2,3-triazol-1-yl)eth-686
yl]boronic Acid (19d): Cream-colored solid (reaction time 16 h, 60%
overall yield), m.p. 185–187 °C dec. [α]D20 = –69.4 (c = 0.7, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 3.32 (dd, J = 14.2, 10.2 Hz, 1
H, BCHCH2), 3.41 (dd, J = 14.2, 5.6 Hz, 1 H, BCHCH2), 4.76 (dd,
J = 10.2, 5.6 Hz, 1 H, BCH), 7.30–7.44 (m, 3 H, Harom), 7.54 (dd,691
J = 5.0, 2.9 Hz, 1 H, Harom), 7.75 (s, 1 H, Harom), 7.79 (d, J =
1.9 Hz, 1 H, Harom), 7.84 (d, J = 6.8 Hz, 1 H, Harom), 8.28 (s, 1 H,
CHtriaz) ppm. 13C NMR (100 MHz, CD3OD): δ = 38.8, 55.2 (br.,
CB), 124.1 (2 C), 126.6, 128.3, 129.3, 129.7, 131.1, 132.2, 134.5,
134.6, 139.7, 142.9, 169.5 ppm. HRMS (ESI-TOF) m/z: calcd. for696
C15H15BN3O4S [M + H]+ 344.0874; found 344.0873.
[(1R)-2-(3-Carboxyphenyl)1-(4-phenoxymethyl-3-yl-1,2,3-triazol-1-
yl)ethyl]boronic Acid (19e): White solid (reaction time 8 h, 54%
overall yield), m.p. 182–184 °C dec. [α]D20 = –37.1 (c = 1.3, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 3.21 (dd, J = 14.1, 10.1 Hz, 1701
H, BCHCH2), 3.32 (dd, J = 14.1, 5.6 Hz, 1 H, BCHCH2), 4.72 (dd,
www.eurjoc.org © 0000 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Eur. J. Org. Chem. 0000, 0–08
J = 10.1, 5.6 Hz, 1 H, BCH), 5.10 (s, 2 H, OCH2), 6.92–6.96 (m, 3
H, Harom), 7.17–7.28 (m, 4 H, Harom), 7.71 (s, 1 H, Harom), 7.82 (d,
J = 7.7 Hz, 1 H, Harom), 7.89 (s, 1 H, CHtriaz) ppm. 13C NMR
(100 MHz, CD3OD): δ = 39.2, 53.6 (br., CB), 62.1, 116.0, 122.3, 706
127.1, 129.1, 129.6, 130.5, 131.2, 132.1, 134.6, 139.9, 159.6,
169.6 ppm, C-4 triazole ring not seen. HRMS (ESI-TOF) m/z:
calcd. for C18H19BN3O5 [M + H]+ 368.1416; found 368.1411.
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